Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | ZN-c5 |
| Synonyms | |
| Therapy Description |
ZN-c5 is a selective estrogen receptor degrader, which prevents estrogen receptor mediated signaling (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| ZN-c5 | ZNc5|ZN c5 | ZN-c5 is a selective estrogen receptor degrader, which prevents estrogen receptor mediated signaling (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT03560531 | Phase I | Palbociclib + ZN-c5 ZN-c5 | A Study of ZN-c5 in Subjects With Breast Cancer | Completed | USA | LTU | HUN | CZE | 5 |
| NCT04176757 | Phase I | ZN-c5 | A Study of ZN-c5 in Participants With Breast Cancer | Completed | USA | AUS | 1 |